JP2021515784A5 - - Google Patents
Info
- Publication number
- JP2021515784A5 JP2021515784A5 JP2020547392A JP2020547392A JP2021515784A5 JP 2021515784 A5 JP2021515784 A5 JP 2021515784A5 JP 2020547392 A JP2020547392 A JP 2020547392A JP 2020547392 A JP2020547392 A JP 2020547392A JP 2021515784 A5 JP2021515784 A5 JP 2021515784A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide according
- chimeric oligonucleotide
- nucleoside
- nucleic acid
- modified
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642499P | 2018-03-13 | 2018-03-13 | |
| US62/642,499 | 2018-03-13 | ||
| PCT/EP2019/056312 WO2019175260A2 (en) | 2018-03-13 | 2019-03-13 | Modified oligonucleotides and methods of use in tauopathies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021515784A JP2021515784A (ja) | 2021-06-24 |
| JP2021515784A5 true JP2021515784A5 (https=) | 2022-03-14 |
| JPWO2019175260A5 JPWO2019175260A5 (https=) | 2022-03-14 |
Family
ID=65861258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547392A Pending JP2021515784A (ja) | 2018-03-13 | 2019-03-13 | 修飾オリゴヌクレオチド及びタウオパチーにおける使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11453881B2 (https=) |
| EP (2) | EP3765476B1 (https=) |
| JP (1) | JP2021515784A (https=) |
| KR (1) | KR20200131263A (https=) |
| CN (1) | CN111868068A (https=) |
| AU (1) | AU2019233612A1 (https=) |
| BR (1) | BR112020018365A2 (https=) |
| CA (1) | CA3091979A1 (https=) |
| EA (1) | EA202092156A1 (https=) |
| ES (1) | ES3063421T3 (https=) |
| IL (1) | IL277238A (https=) |
| MA (1) | MA52149A (https=) |
| MX (1) | MX2020009532A (https=) |
| SG (1) | SG11202008895WA (https=) |
| WO (1) | WO2019175260A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013203395A1 (en) | 2012-03-30 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome |
| TWI772856B (zh) | 2013-07-19 | 2022-08-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| WO2021198958A1 (en) * | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Nucleic acid polymers |
| PE20240648A1 (es) * | 2021-07-23 | 2024-04-04 | Biogen Ma Inc | Metodos para reducir la expresion de tau |
| AU2024313057A1 (en) * | 2023-06-22 | 2025-10-30 | Denali Therapeutics Inc. | Compositions and methods for modulating tau expression |
| US12551569B2 (en) | 2024-03-31 | 2026-02-17 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use |
| WO2026025082A1 (en) * | 2024-07-25 | 2026-01-29 | Biogen Ma Inc. | Methods for treating alzheimer's disease |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| CZ296576B6 (cs) | 1999-02-12 | 2006-04-12 | Sankyo Company Limited | Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem |
| US7084125B2 (en) | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
| EP1178999B1 (en) | 1999-05-04 | 2007-03-14 | Santaris Pharma A/S | L-ribo-lna analogues |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| JP4151751B2 (ja) | 1999-07-22 | 2008-09-17 | 第一三共株式会社 | 新規ビシクロヌクレオシド類縁体 |
| CN1317291C (zh) * | 1999-09-10 | 2007-05-23 | 杰龙公司 | 寡核苷酸n3′→p5′硫代氨基磷酸酯,其合成及应用 |
| US7569575B2 (en) | 2002-05-08 | 2009-08-04 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
| CA2504694C (en) | 2002-11-05 | 2013-10-01 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| DK1794313T3 (da) * | 2004-06-21 | 2013-07-22 | Proteome Sciences Plc | Fremgangsmåde til screeninger der anvender C-ABL, FYN og SYK i kombination med tau-protein |
| GB0605337D0 (en) | 2006-03-17 | 2006-04-26 | Genomica Sau | Treatment of CNS conditions |
| CN109810977A (zh) * | 2012-05-26 | 2019-05-28 | 株式会社博纳克 | 具有递送功能的基因表达调控用单链核酸分子 |
| US9228189B2 (en) * | 2012-10-26 | 2016-01-05 | Geron Corporation | C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders |
| ES2807379T3 (es) * | 2013-03-14 | 2021-02-22 | Ionis Pharmaceuticals Inc | Composiciones y métodos para regular la expresión de Tau |
| TWI772856B (zh) * | 2013-07-19 | 2022-08-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| CA2971830A1 (en) * | 2014-12-29 | 2016-07-07 | Bonac Corporation | Composition containing nucleic acid molecule stably |
| AU2016215155A1 (en) * | 2015-02-04 | 2017-08-17 | F. Hoffmann-La Roche Ag | Tau antisense oligomers and uses thereof |
| PH12018501207B1 (en) * | 2015-12-21 | 2024-02-23 | Novartis Ag | Compositions and methods for decreasing tau expression |
-
2019
- 2019-03-13 KR KR1020207027936A patent/KR20200131263A/ko not_active Ceased
- 2019-03-13 JP JP2020547392A patent/JP2021515784A/ja active Pending
- 2019-03-13 AU AU2019233612A patent/AU2019233612A1/en not_active Abandoned
- 2019-03-13 CA CA3091979A patent/CA3091979A1/en active Pending
- 2019-03-13 EP EP19712535.4A patent/EP3765476B1/en active Active
- 2019-03-13 EA EA202092156A patent/EA202092156A1/ru unknown
- 2019-03-13 BR BR112020018365-2A patent/BR112020018365A2/pt not_active Application Discontinuation
- 2019-03-13 WO PCT/EP2019/056312 patent/WO2019175260A2/en not_active Ceased
- 2019-03-13 SG SG11202008895WA patent/SG11202008895WA/en unknown
- 2019-03-13 MX MX2020009532A patent/MX2020009532A/es unknown
- 2019-03-13 ES ES19712535T patent/ES3063421T3/es active Active
- 2019-03-13 EP EP21170299.8A patent/EP3922637A1/en active Pending
- 2019-03-13 US US16/980,389 patent/US11453881B2/en active Active
- 2019-03-13 CN CN201980018910.3A patent/CN111868068A/zh active Pending
- 2019-03-13 MA MA052149A patent/MA52149A/fr unknown
-
2020
- 2020-09-09 IL IL277238A patent/IL277238A/en unknown
-
2022
- 2022-09-26 US US17/935,518 patent/US20240011029A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021515784A5 (https=) | ||
| JP7478210B2 (ja) | 修飾オリゴヌクレオチド及び使用方法 | |
| JP7798836B2 (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| JP2016513976A5 (https=) | ||
| JP2023109824A (ja) | ＧａｌＮＡｃ誘導体 | |
| US20170362270A1 (en) | Modified oligonucleotides and methods for their synthesis | |
| KR20200024793A (ko) | 알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법 | |
| CN121079412A (zh) | 经修饰的指导rna | |
| JP2021515784A (ja) | 修飾オリゴヌクレオチド及びタウオパチーにおける使用方法 | |
| BR112020010090A2 (pt) | oligonucleotídeo gapmer, sal farmaceuticamente aceitável do mesmo, conjugado, composição farmacêutica e uso dos mesmos | |
| TWI791868B (zh) | 調節rtel1表現之寡核苷酸 | |
| JP2020521491A5 (https=) | ||
| JPWO2019175260A5 (https=) | ||
| JP2018518167A5 (https=) | ||
| TW202313068A (zh) | 用於抑制黏蛋白５ＡＣ（ＭＵＣ５ＡＣ）表現之ＲＮＡｉ藥劑、其組合物及使用方法 | |
| WO2003062258A1 (en) | Rnase l activator-antisense complexes | |
| WO2021157730A1 (ja) | 核酸医薬とその使用 | |
| JP7813254B2 (ja) | Ｆｕｂｐ１発現を調節するための増強されたオリゴヌクレオチド | |
| BR112020012427A2 (pt) | oligonucleotídeo, sal farmaceuticamente aceitável, conjugado, composição farmacêutica, processo para a fabricação de um oligonucleotídeo, oligonucleotídeo fabricado e invenção | |
| TW202345861A (zh) | 經修飾之間隔體寡聚物及其使用方法 | |
| JPWO2023097291A5 (https=) | ||
| JPWO2022204430A5 (https=) | ||
| US20240287512A1 (en) | Lipid conjugation for targeting neurons of the central nervous system | |
| US20240011023A1 (en) | Hybridized guide nucleic acids for use with template-based gene editors | |
| JPWO2023102488A5 (https=) |